Founded in 2013 by two Harvard Medical School-affiliated doctors, Donna Brezinski MD and Gary Gilbert MD, Little Sparrows Technologies offers an innovative approach for the treatment of neonatal jaundice. In addition to the bili•hutTm, the company offers additional products for the treatment of jaundice including the bili•rulerTm jaundice screening device.
What is neonatal jaundice?

60% of newborns develop jaundice in the first week of their lives.

Neonatal jaundice (hyperbilirubinemia) is one of the most common neonatal conditions and is one of the leading causes of hospital readmissions worldwide. It is caused by elevated levels of bilirubin, a breakdown product of red blood cells. When severe jaundice is left untreated, it can lead to serious medical issues such as kernicterus, a type of permanent brain injury. Nearly all babies can be cured with timely, effective phototherapy.

Globally, an estimated 6 million newborns do not receive treatment for severe jaundice because they lack access to effective phototherapy devices. Annually, severe neonatal jaundice is a significant cause of preventable newborn deaths in resource poor areas, and survivors suffer lifelong neurological disability as a result of the condition.

We created bili-hut to provide the most clinically effective phototherapy treatment available to treat infant jaundice.